KALV
KalVista Pharmaceuticals, Inc.NASDAQHealthcare$19.90+0.66%ClosedMarket Cap: $1.02B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-376.36
P/S
13.78
EV/EBITDA
-6.65
DCF Value
$2.06
FCF Yield
-7.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
68.7%
Operating Margin
-231.1%
Net Margin
-222.8%
ROE
-444.4%
ROA
-49.8%
ROIC
-57.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 2026 | $59.9M | 90.4% | $-13.3M | $-5.4M | $-0.11 | — |
| Q2 2026 | $13.7M | 91.0% | $-46.0M | $-49.5M | $-0.92 | — |
| Q1 2026 | $1.4M | 58.6% | $-59.0M | $-60.1M | $-1.12 | — |
| Q4 2025 | $0.00 | -Infinity% | $-55.0M | $-52.2M | $-1.05 | — |
| FY 2025 | $0.00 | NaN% | $-188.0M | $-183.4M | $-3.69 | — |
| Q3 2025 | $0.00 | NaN% | $-42.9M | $-48.5M | $-0.92 | — |
| Q2 2025 | $0.00 | NaN% | $-45.8M | $-42.3M | $-0.91 | — |
| Q1 2025 | $0.00 | NaN% | $-44.2M | $-40.4M | $-0.87 | — |
| Q4 2024 | $0.00 | -Infinity% | $-48.5M | $-44.6M | $-1.02 | — |
| FY 2024 | $0.00 | -Infinity% | $-140.4M | $-126.6M | $-3.44 | — |
| Q3 2024 | $0.00 | -Infinity% | $-33.2M | $-29.0M | $-0.84 | — |
| Q2 2024 | $0.00 | -Infinity% | $-29.7M | $-27.6M | $-0.80 | — |